The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | The treatment of relapsed/refractory chronic lymphocytic leukemia
Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, summarises her highlights of the 20th Congress of the European Hematology Association (EHA), including the results of a phase 1b trial that showed the combination of venetoclax (ABT-199/GDC-0199) and rituximab induces deep responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL); and the long-term follow-up results of a trial that evaluated the safety and clinical activity of idelalisib in patients with relapsed or refractory CLL.
